ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Noninvasive prediction of lymphovascular invasion in rectal cancer without lymph node metastasis using a SHAP-interpretable combined model integrating MRI radiomics features and clinical immune-inflammatory biomarkers: a bicenter study.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundLymphovascular invasion (LVI) status in rectal cancer (RC) without lymph node metastasis (LNM) can significantly influence the patient's treatment decisions. This study aims to develop and validate a combined model based on MRI radiomics features integrated with clinical immune-inflammatory biomarkers for the prediction of LVI status in RC without LNM. The Shapley Additive Explanation (SHAP) method was employed to visualize the prediction process and enhance interpretability for clinical application.
methodsWe retrospectively collected data from 257 RC patients without LNM from two centers. Univariate and multivariate logistic regression analyses were performed on clinical data to identify independent predictors of LVI. Volumes of interest were manually delineated on T2WI and ADC sequences, and corresponding radiomic features were extracted. A combined model was constructed by combining rad-score and clinical immune-inflammatory biomarkers, and the SHAP was used to visualize the prediction process.
resultsThe area under the curve (AUC) of the combined model was based on intratumoral features (training vs. testing vs. validation datasets: 0.813 vs. 0.854 vs. 0.807). The AUC of the combined model was based on both intra- and peritumoral features (training vs. testing vs. validation datasets: 0.855 vs. 0.841 vs. 0.860). After comparison, the combined model (C + Q) based on intra- and peritumoral MRI radiomics features integrated with clinical immune-inflammatory biomarkers demonstrated better predictive performance.
conclusionThe combined model (C + Q) has great potential in the non-invasive prediction of LVI in RC without LNM, providing a basis for stratified management and individualized treatment decisions for RC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.